BioMarin gains on Phase II achondroplasia data

BioMarin Pharmaceutical Inc. (NASDAQ:BMRN) gained $7.95 to $131.55 in after-hours trading Wednesday after reporting results from a Phase II trial of vosoritide ( BMN 111) in 26 children aged 5-14 with achondroplasia, a form of dwarfism.

The 10 patients receiving the highest vosoritide dose of 15 ug/kg had a mean increase of 50% in annualized six-month growth velocity compared to baseline (p=0.01). BioMarin hopes to move the 15 ug/kg dose into pivotal studies following discussions with regulatory authorities. EVP and CMO Henry Fuchs said on a conference call that "achieving a 50% increase in growth velocity essentially returns subjects to their normal growth rate." ...